Henan Newland Pharmaceutical Co. Ltd. A - Asset Resilience Ratio
Henan Newland Pharmaceutical Co. Ltd. A (301277) has an Asset Resilience Ratio of 29.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See 301277 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301277 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥542.35 Million | 29.76% |
| Total Liquid Assets | CN¥542.35 Million | 29.76% |
Asset Resilience Insights
- Very High Liquidity: Henan Newland Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 29.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Henan Newland Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Henan Newland Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Henan Newland Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.88% | CN¥549.55 Million ≈ $80.42 Million |
CN¥1.78 Billion ≈ $260.40 Million |
+1.93pp |
| 2024-12-31 | 28.95% | CN¥525.16 Million ≈ $76.85 Million |
CN¥1.81 Billion ≈ $265.41 Million |
-7.67pp |
| 2023-12-31 | 36.63% | CN¥589.50 Million ≈ $86.26 Million |
CN¥1.61 Billion ≈ $235.52 Million |
-9.10pp |
| 2022-12-31 | 45.73% | CN¥701.36 Million ≈ $102.63 Million |
CN¥1.53 Billion ≈ $224.44 Million |
+44.43pp |
| 2021-12-31 | 1.30% | CN¥8.67 Million ≈ $1.27 Million |
CN¥667.90 Million ≈ $97.74 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more